The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | “Watch and wait” versus treatment in smoldering myeloma: insights from AQUILA trial
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, shares her thoughts on the ongoing debate about the “watch and wait” approach in smoldering multiple myeloma (SMM), citing the recent AQUILA trial (NCT03301220) as a significant study. Dr Raje states that while the trial showed a progression-free survival and overall survival (PFS; OS) benefit with daratumumab, this benefit was mainly seen in ultra-high-risk patients, suggesting that these patients may be the ones who truly benefit from treatment. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
